Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Using Quantitative Retinal SD-OCT Features to Predict Eyes at Risk of Fast Expansion of Geographic Atrophy in Dry Age-related Macular Degeneration
Author Affiliations & Notes
  • Bassel Hammoud
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Karen Matar
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Yavuz Cakir
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Reem Amine
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Hasan Cetin
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Gagan Kalra
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Sari Yordi
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Michelle Bonnay
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Jamie Reese
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Sunil K Srivastava
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Hannah Yu
    Retina Consultants of Texas, Texas, United States
  • Charles Clifton Wykoff
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Justis Ehlers
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   Bassel Hammoud None; Karen Matar None; Yavuz Cakir None; Reem Amine None; Hasan Cetin None; Gagan Kalra None; Sari Yordi None; Michelle Bonnay None; Jamie Reese None; Sunil Srivastava Bausch and Lomb, Adverum, Novartis, and Regeneron, Code C (Consultant/Contractor), Regeneron, Allergan, and Gilead, Code F (Financial Support), Leica, Code P (Patent); Hannah Yu None; Charles Wykoff Alimera Sciences, Allegro, Allergan, Alynylam, Apellis, Bayer, Clearside, D.O.R.C., EyePoint, Genentech/Roche, Kodiak, Notal Vision, Novartis, ONL Therapeutics, PolyPhotonix, RecensMedical, Regeneron, Regenxbio, Santen, Code C (Consultant/Contractor), Adverum, Allergan, Apellis, Clearside, EyePoint, Genentech/Roch, Neurotech, Novartis, Opthea, Regeneron, Regenxbio, Samsung, Santen, Code F (Financial Support), Regeneron, Code S (non-remunerative); Justis Ehlers Zeiss, Leica/Bioptigen, Alcon, Beyeonics. Allergan, Allegro, Adverum, Regeneron, Roche, Genentech, RegenxBIO, Iveric Bio, Boehringer Ingelheim, Apellis, Novartis, Boehringer Ingelheim, Stealth Biotherapeutics, Perceive Biotherapeutics, Exegenesis, Ophthalytics, Eyepoint, Abbvie, Bayer, BVI, Alexion, Code C (Consultant/Contractor), Regeneron, Genentech, Oxurion/Thrombogenics, Alcon, Aerpio, Allergan, Roche, Iveric Bio, Boehringer Ingelheim, Adverum, Novartis, Zeiss, Stealth Biotherapeutics, Perceive Biotherapeutics, Alexion, Beyeonic, Code F (Financial Support), Bioptigen/Leica, Code P (Patent)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 1432. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Bassel Hammoud, Karen Matar, Yavuz Cakir, Reem Amine, Hasan Cetin, Gagan Kalra, Sari Yordi, Michelle Bonnay, Jamie Reese, Sunil K Srivastava, Hannah Yu, Charles Clifton Wykoff, Justis Ehlers; Using Quantitative Retinal SD-OCT Features to Predict Eyes at Risk of Fast Expansion of Geographic Atrophy in Dry Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2024;65(7):1432.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Geographic atrophy (GA) is an advanced stage of dry age-related macular degeneration (AMD). With the recent advances in therapies aiming at slowing disease progression, predicting patients at risk of fast GA expansion could be particularly useful, not only for clinical prognostication, but also for targeting patients who would benefit most from treatment. The goal of this study was to develop a prediction model for patients at risk of fast GA expansion within 1 year, based on retinal quantitative features.

Methods : This was an IRB-approved retrospective longitudinal study, that included baseline and 1-year follow up SD-OCT scans from 311 eyes of 311 patients with geographic atrophy. A previously validated deep learning-based platform was used for automated segmentation of multiple retinal layers with segmentation validation performed by certified readers. This allowed for extraction of several quantitative features describing photoreceptor integrity and disease burden. Patients were then split based on their 1-year GA expansion rate into fast (> 2 mm2/year) and normal/slow (< 2 mm2/year) progressors. To predict risk of fast expansion, a random forest (RF) classification model was trained on 70% of the data and tested on the remaining 30%. A Shapley additive explanations (SHAP) analysis was then performed to explain the output of the RF model.

Results : The mean GA growth rate in the slow/normal progressor group was 0.5 ± 0.5 mm2/year vs 2.9 ± 0.9 mm2/year for the fast progressor group (p-value < 0.001). The preliminary prediction model had a sensitivity of 89%, specificity of 88%, positive predictive value of 82%, negative predictive value of 93%, and accuracy of 88%. The mean GA growth rate in the misclassified patients was 1.9 ± 0.5 mm2/year which was at the boundary that defined the 2 groups. The SHAP analysis revealed that larger GA area, larger area of partial photoreceptor attenuation (EZ-RPE thickness ≤ 20 microns), and high drusen burden were the most significant contributors to the model’s predictions.

Conclusions : This work shows that OCT-extracted quantitative metrics carry significant value for predicting patients at risk of 1-year fast GA expansion. Future work will focus on fine tuning this model and external dataset validation.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×